Skip to content
Search

Latest Stories

UK may signal green for emergency ventilator production

British industry expects the government to give the go-ahead to an emergency ventilator production plan on Wednesday (25) that will see a number of firms join forces to tackle the coronavirus outbreak, three sources told.

Airbus, Smiths, Ford and McLaren are among a number of different firms which will be involved in the process, with the idea that some degree of output, whether that is making components or full ventilators, should ideally begin next week, said a source close to the process.


"It will be upscaling, on more of an industrial scale, existing ventilator designs," one of the sources said.

Companies will provide a range of expertise including 3D printing, manufacturing specific parts, assembly and business planning. The government will make an announcement on Wednesday, the sources said.

Britain is trying to boost the number of ventilators available to its publicly funded health service by using some from private hospitals and building more domestically if possible.

The British government declined to comment on the exact timing or details of the ventilator production plan.

The pandemic has forced doctors in some countries to either ration or plan limiting access to critical care beds and ventilators with many nations scrambling to make or buy more.

Ventilators, which cost tens of thousands of dollars, are mechanical breathing devices that can blow air and oxygen into the lungs.

They are crucial for the care of people with lung failure, which can be one of the complications suffered by patients with severe COVID-19, the disease coronavirus causes. But they don’t necessarily save people.

British prime minister Boris Johnson asked businesses to help make the devices over a week ago when he spoke to more than 60 manufacturing firms and organizations with a number of aerospace and automotive companies contacted.

"Businesses can get involved in any part of the process: design, procurement, assembly, testing, and shipping," his Downing Street office said in a statement on March 16.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less